Claims for Patent: 7,323,493

Summary for Patent: 7,323,493

Title:	Solid pharmaceutical composition containing benzofuran derivatives
Abstract:	The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.
Inventor(s):	Abramovici; Bernard (Juvignac, FR), Gautier; Jean-Claude (Clapiers, FR), Gromenil; Jean-Claude (Mountbazin, FR), Marrier; Jean-Marie (Lattes, FR)
Assignee:	Sanofi-Aventis (Paris, FR)
Application Number:	09/446,601
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,323,493
Patent Claims:	1. A solid pharmaceutical composition in tablet form for oral administration comprising a benzofuran derivative with antiarrhythmic activity selected from the group consisting of dronedarone and amiodarone, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant selected from poloxamers, optionally in combination with one or more pharmaceutical excipients, said nonionic hydrophilic surfactant being present in a proportion of from 5% to 15% by weight of the active principle in base form, provided that the pharmaceutical composition does not contain a polysorbate surfactant. 2. A pharmaceutical composition according to claim 1 wherein the pharmaceutically acceptable salt is the hydrochloride. 3. A pharmaceutical composition according to claim 2, wherein the benzofuran derivative is dronedarone hydrochloride. 4. A pharmaceutical composition according to claim 2, wherein the benzofuran derivative is amiodarone hydrochloride. 5. A pharmaceutical composition according to claim 1 wherein the nonionic hydrophilic surfactant is selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407. 6. A pharmaceutical composition according to claim 5 wherein the nonionic hydrophilic surfactant is poloxamer 407. 7. A pharmaceutical composition according to claim 6 wherein the benzofuran derivative is dronedarone hydrochloride. 8. A pharmaceutical composition according to claim 6 wherein the benzofuran derivative is amiodarone hydrochloride. 9. A pharmaceutical composition according to claim 5 containing from 50 to 500 mg of active principle. 10. A pharmaceutical composition according to claim 9, containing from 200 to 400 mg of active principle. 11. A pharmaceutical composition according to claim 10, containing from 200 to 400 mg of active principle, calculated in base form, and 10% by weight of nonionic hydrophilic surfactant relative to the active principle in base form. 12. A pharmaceutical composition according to claim 11 wherein the active principle is selected from the group consisting of amiodarone hydrochloride and dronedarone hydrochloride or a pharmaceutically acceptable salt thereof. 13. A pharmaceutical composition according to claim 12 wherein the nonionic hydrophilic surfactant is poloxamer 407. 14. A pharmaceutical composition according to claim 13 wherein the active principle is dronedarone hydrochloride.